Suppr超能文献

广泛耐药结核病是什么;如何治疗;以及为什么治疗失败率如此之高?

XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?

作者信息

Gillespie Stephen H, Singh Kasha

机构信息

Sir James Black Professor of Medicine, University of St Andrews, Medical School, North Haugh, St Andrews, KY16 9TF, USA.

出版信息

Recent Pat Antiinfect Drug Discov. 2011 May;6(2):77-83. doi: 10.2174/157489111796064641.

Abstract

Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.

摘要

耐药性是全球抗击结核病(TB)的主要障碍。在解决这一问题时,了解耐药性如何产生以及如何成功治疗耐多药和广泛耐药结核病(M/XDR-TB)都很重要。治疗的最大问题是缺乏有效药物。近年来,这一领域取得了令人振奋的进展,从旧药中发现了有用的药物,也有新的发现。新型药物正在申请专利,旧药如硫利达嗪也可能有新用途。如果我们要在M/XDR-TB的管理上取得进展,一个蓬勃发展的药物研发渠道至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验